Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while State Street SPDR S&P Homebuilders ETF trades at $92.84 (market cap $1.49B). The key difference: State Street SPDR S&P Homebuilders ETF is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and State Street SPDR S&P Homebuilders ETF for 35 Days on average.
| MRVI | XHB | |
|---|---|---|
Market Cap | $972.90M | $1.49B |
Volume | 4,325,710 | 1,578,908 |
Sector | Health | Broad Market / Factor |
52-Week High | $9.00 | $121.36 |
52-Week Low | $2.83 | $92.84 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.70, up 0.69% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. Recent news highlights mixed housing data, with rising mortgage rates pressuring the sector but new legislation and institutional interest offering potential support. The ETF lacks current fundamental ratio data but tracks homebuilder stocks sensitive to economic cycles.
The outlook for XHB hinges on housing market dynamics; opportunities exist if affordability improves or construction accelerates, but risks include persistent high rates and economic slowdowns. Investor sentiment is cautious amid volatile home sales data, requiring close watch on macroeconomic indicators for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
